OncoZenge AB (publ) (ONCOZ.ST)
SEK 3.97
(4.34%)
SEK 3.97
(4.34%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 3000.00 | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | 3000.00 | - | - | - |
| Operating Expenses | 15.9 Million | 43.56 Million | 4.89 Million | 801 Thousand |
| Selling, General and Administrative Expenses | 8.5 Million | 5.92 Million | 4.67 Million | 801 Thousand |
| Research and Development Expenses | - | 37.63 Million | 216 Thousand | - |
| Other Expenses | 7.39 Million | 2000.00 | - | - |
| Cost and Expenses | 15.9 Million | 43.56 Million | 4.89 Million | 801 Thousand |
| Operating Income | -15.9 Million | -43.56 Million | -4.89 Million | -801 Thousand |
| Interest Expense | - | - | - | - |
| Income Tax Expense | - | 3.07 Million | -1 Million | -165 Thousand |
| Earnings before Tax | -15.9 Million | -43.56 Million | -4.89 Million | -801 Thousand |
| Net Income | -15.9 Million | -46.64 Million | -3.88 Million | -636 Thousand |
| Earnings Per Share Basic | -1.36 | -3.98 | -0.33 | -0.04 |
| Earnings Per Share Diluted | -1.36 | -3.98 | -0.33 | -0.04 |
| Weighted Average Shares Outstanding | 11.71 Million | 11.71 Million | 11.71 Million | 14.54 Million |
| Weighted Average Shares Outstanding (Diluted) | 11.71 Million | 11.71 Million | 11.71 Million | 14.54 Million |
| Gross Margin | 1.00 | - | - | - |
| EBIT Margin | 2422.00 | - | - | - |
| Profit Margin | -5300.67 | - | - | - |
| EBITDA | 7.26 Million | -43.56 Million | -4.89 Million | -801 Thousand |
| Earnings Before Tax Margin | -5300.67 | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 1000.00 | - | 3000.00 | 3000.00 | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | 1000.00 | - | 3000.00 | 3000.00 | - | - |
| Operating Expenses | 2.04 Million | 2.37 Million | 3.17 Million | 15.9 Million | 4.18 Million | 4.49 Million |
| Selling, General and Administrative Expenses | 2.04 Million | 2.37 Million | 2.24 Million | - | 2.79 Million | 1.32 Million |
| Research and Development Expenses | 573 Thousand | - | 928 Thousand | - | 1.38 Million | 3.16 Million |
| Other Expenses | -572.99 Thousand | - | - | - | - | - |
| Cost and Expenses | 2.04 Million | 2.37 Million | 3.17 Million | 15.9 Million | 4.18 Million | 4.49 Million |
| Operating Income | -2.04 Million | -2.37 Million | -3.17 Million | -15.9 Million | -4.18 Million | -4.49 Million |
| Interest Expense | 4000.00 | - | - | - | - | - |
| Income Tax Expense | -2.04 Million | -2.37 Million | 3000.00 | -23.16 Million | -5792.00 | -6792.00 |
| Earnings before Tax | -2.05 Million | -2.37 Million | -3.17 Million | -15.9 Million | -4.18 Million | -4.49 Million |
| Net Income | -2.05 Million | -2.37 Million | -3.17 Million | -15.9 Million | -4.18 Million | -4.49 Million |
| Earnings Per Share Basic | -0.18 | -0.20 | -0.27 | - | -0.36 | -0.38 |
| Earnings Per Share Diluted | -0.18 | -0.20 | -0.27 | - | -0.36 | -0.38 |
| Weighted Average Shares Outstanding | 11.71 Million | 11.71 Million | 11.71 Million | 11.71 Million | 11.71 Million | 11.71 Million |
| Weighted Average Shares Outstanding (Diluted) | 11.71 Million | 11.71 Million | 11.71 Million | 11.71 Million | 11.71 Million | 11.71 Million |
| Gross Margin | 1.00 | - | 1.00 | 1.00 | - | - |
| EBIT Margin | -2049.00 | - | -1056.67 | - | - | - |
| Profit Margin | -2053.00 | - | -1056.67 | -5300.67 | - | - |
| EBITDA | -2.04 Million | -2.37 Million | -3.17 Million | - | -4.18 Million | -4.49 Million |
| Earnings Before Tax Margin | -2049.00 | - | -1057.67 | -5300.67 | - | - |
ELECON
AZMTF
RSAU
EML
PRAXIS
MMND